Follow
Valentina Agnolon
Valentina Agnolon
CHUV, Lausanne, Switzerland
Verified email at chuv.ch - Homepage
Title
Cited by
Cited by
Year
Synthesis, spectroscopic, and photophysical characterization and photosensitizing activity toward prokaryotic and eukaryotic cells of porphyrin-magainin and-buforin conjugates
R Dosselli, R Ruiz-Gonzalez, F Moret, V Agnolon, C Compagnin, ...
Journal of medicinal chemistry 57 (4), 1403-1415, 2014
662014
Trimeric SARS-CoV-2 spike proteins produced from CHO cells in bioreactors are high-quality antigens
P Pino, J Kint, D Kiseljak, V Agnolon, G Corradin, AV Kajava, P Rovero, ...
Processes 8 (12), 1539, 2020
222020
ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with …
V Agnolon, A Contato, A Meneghello, E Tagliabue, G Toffoli, M Gion, ...
Scientific Reports 10 (1), 3016, 2020
202020
The potential of adjuvants to improve immune responses against TdaP vaccines: a preclinical evaluation of MF59 and monophosphoryl lipid A
V Agnolon, C Bruno, R Leuzzi, B Galletti, U D’Oro, M Pizza, A Seubert, ...
International Journal of Pharmaceutics 492 (1-2), 169-176, 2015
192015
Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines
V Agnolon, C Bruno, B Galletti, E Mori, M Ugozzoli, C Pergola, ...
Vaccine 34 (8), 1040-1046, 2016
182016
The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine
C Bruno, V Agnolon, F Berti, S Bufali, DT O’Hagan, BC Baudner
European Journal of Pharmaceutics and Biopharmaceutics 105, 1-8, 2016
162016
Designs and characterization of subunit Ebola GP vaccine candidates: implications for immunogenicity
V Agnolon, D Kiseljak, MJ Wurm, FM Wurm, C Foissard, F Gallais, ...
Frontiers in immunology 11, 586595, 2020
92020
Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels
ASC Fabricio, S Michilin, M Zancan, V Agnolon, L Peloso, R Dittadi, ...
Scandinavian Journal of Clinical and Laboratory Investigation 79 (4), 260-267, 2019
82019
P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine
I Ayadi, S Balam, R Audran, JP Bikorimana, I Nebie, M Diakité, I Felger, ...
Frontiers in immunology 11, 574330, 2020
62020
Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa
S Balam, K Miura, I Ayadi, D Konaté, NC Incandela, V Agnolon, ...
bioRxiv, 2024
2024
Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa
M Arévalo-Herrera, S Balam, K Miura, I Ayadi, D Konaté, NC Incandela, ...
bioRxiv, 2024.04. 10.588966, 2024
2024
Ebola vaccine compositions and methods of using same
D Kiseljak, FM Wurm, V Agnolon, F Spertini, B Correia
US Patent App. 17/271,657, 2021
2021
Trimeric SARS-CoV-2 Spike proteins produced from CHO-cells in bioreactors are high-quality antigens (preprint)
P Pino, D Kiseljak, V Agnolon, G Corradin, AV KAJAVA, P Rovero, ...
2020
Design and characterization of near-native Ebola GP vaccine candidates: implications for immunogenicity
V Agnolon, I Ayadi, JP Bikorimana, D Kiseljak, V De Vaux, S Wehrle, ...
Swiss Medical Weekly 148, 6S-7S, 2018
2018
COMPARISON BETWEEN OVARIAN MALIGNANCY ALGORITHM (ROMA) AND IOTA RISK MODEL (LR2) FOR DIFFERENTIAL DIAGNOSIS OF ADNEXAL MASSES: REAL-WORLD STUDY
C Romagnolo, ASC Fabricio, AE Leon, M Taborelli, V Agnolon, ...
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 27, 421-421, 2017
2017
A formulation science perspective applied to combination vaccines: particles-based multiplex immunoassays for improved antigens characterization and rational design of …
V Agnolon
Universitŕ degli studi di Padova, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–16